FCGR2B and systemic lupus erythematosus: Because there are several underlying molecular mechanisms of lupus, tailoring treatment for patients concerning the possible molecular differences using the targeted drug might be one of the interesting futures of “personalized medicine” in lupus patients with FcγRIIb dysfunction polymorphism and/or leaky gut.